on December 16, 2002
Circulation. 2002
Published online before print December 16, 2002, doi: 10.1161/01.CIR.0000044914.42696.6A
Published online before print December 16, 2002, doi: 10.1161/01.CIR.0000044914.42696.6A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 1, 2002
From the Department of Medicine, Columbia Presbyterian Medical Center, New York, NY. * To whom correspondence should be addressed. E-mail: dmm31{at}columbia.edu.
Background—Patients with chronic heart failure (CHF) are frequently anemic. An increase in hemoglobin could enhance exercise performance by increasing oxygen delivery. We investigated the effect of erythropoietin (EPO) on exercise performance in anemic patients with CHF. Methods and Results—Twenty-six anemic patients aged 57±11 years were randomized to receive EPO (15 000 to 30 000 IU per week) or placebo for 3 months. Parameters measured at baseline and end therapy included blood parameters (hemoglobin, hematocrit, plasma volume), exercise parameters (peak oxygen consumption [|$$·VO2], exercise duration, 6-minute walk), muscle aerobic metabolism (half-time of |$$·VO2 and near infrared recovery), and forearm vasodilatory function. EPO was well tolerated by all patients. Twelve patients in the EPO group felt improvement versus 1 in the placebo group (P<0.05). There were significant increases in hemoglobin (11.0±0.5 to 14.3±1.0 g/dL, P<0.05), peak |$$·VO2 (11.0±1.8 to 12.7±2.8 mL · min-1 · kg-1, P<0.05) and exercise duration (590±107 to 657±119 s, P<0.004) in the EPO group but no significant changes in the control group. Resting and hyperemic forearm vascular resistance and indices of the rate of muscle oxidative capacity were unchanged in both groups. Conclusion—EPO significantly enhances exercise capacity in patients with CHF. One mechanism of improvement in |$$·VO2 is increased oxygen delivery from increased hemoglobin concentration.
Revised on October 3, 2002
Accepted on October 7, 2002
Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure
Donna M. Mancini MD*,
Key words: exercise • heart failure • growth substances
This article has been cited by other articles:
 |
|
 |
|
  M. Klapholz, W. T. Abraham, J. K. Ghali, P. Ponikowski, S. D. Anker, B. Knusel, Y. Sun, S. M. Wasserman, and D. J. van Veldhuisen The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure Eur J Heart Fail, November 1, 2009; 11(11): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Anker, J. C. Colet, G. Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, T. F. Luscher, C. Mori, B. von Eisenhart Rothe, S. Pocock, et al. Rationale and design of Ferinject(R) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia Eur J Heart Fail, November 1, 2009; 11(11): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P van der Meer, H F Groenveld, J L Januzzi Jr, and D J van Veldhuisen Erythropoietin treatment in patients with chronic heart failure: a meta-analysis Heart, August 15, 2009; 95(16): 1309 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray, I. S. Anand, R. Diaz, A. P. Maggioni, C. O'Connor, M. A. Pfeffer, K. R. Polu, S. D. Solomon, Y. Sun, K. Swedberg, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail, August 1, 2009; 11(8): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Goodlin Palliative care in congestive heart failure. J. Am. Coll. Cardiol., July 28, 2009; 54(5): 386 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H.M. van Straten, M. A. Soliman Hamad, A. J. van Zundert, E. J. Martens, J. P.A.M. Schonberger, and A. M. de Wolf Preoperative Hemoglobin Level as a Predictor of Survival After Coronary Artery Bypass Grafting: A Comparison With the Matched General Population Circulation, July 14, 2009; 120(2): 118 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Burger, F.-L. Xiang, L. Hammoud, D. L. Jones, and Q. Feng Erythropoietin Protects the Heart from Ventricular Arrhythmia during Ischemia and Reperfusion via Neuronal Nitric-Oxide Synthase J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 900 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Naito, T. Tsujino, M. Matsumoto, T. Sakoda, M. Ohyanagi, and T. Masuyama Adaptive response of the heart to long-term anemia induced by iron deficiency Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H585 - H593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gao and W. J. Koch Is erythropoietin behind maladaptive anemic heart failure? Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H559 - H560. [Full Text] [PDF]
|
|
|
|
|
|
A. Kazory and E. A. Ross Anemia: the point of convergence or divergence for kidney disease and heart failure? J. Am. Coll. Cardiol., February 24, 2009; 53(8): 639 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biolo, R. Greferath, D. A. Siwik, F. Qin, E. Valsky, K. C. Fylaktakidou, S. Pothukanuri, C. D. Duarte, R. P. Schwarz, J.-M. Lehn, et al. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate PNAS, February 10, 2009; 106(6): 1926 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Pagourelias, C. Koumaras, A. I. Kakafika, K. Tziomalos, P. G. Zorou, V. G. Athyros, and A. Karagiannis Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure? Angiology, February 1, 2009; 60(1): 74 - 81. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure Journal of Pharmacy Practice, December 1, 2008; 21(6): 420 - 423. [Abstract] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur. Heart J., October 1, 2008; 29(19): 2388 - 2442. [Full Text] [PDF]
|
|
|
|
|
|
K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail, October 1, 2008; 10(10): 933 - 989. [Full Text] [PDF]
|
|
|
|
|
|
D. S. Silverberg, D. Wexlerb, A. Iaina, and D. Schwartz The role of correction of anaemia in patients with congestive heart failure: A short review Eur J Heart Fail, September 1, 2008; 10(9): 819 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand Anemia and Chronic Heart Failure: Implications and Treatment Options J. Am. Coll. Cardiol., August 12, 2008; 52(7): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kazory and E. A. Ross Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective Circulation, February 19, 2008; 117(7): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang, W. Tong, A. Jain, G. S. Francis, C. M. Harris, and J. B. Young Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol., February 5, 2008; 51(5): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Ghali, I. S. Anand, W. T. Abraham, G. C. Fonarow, B. Greenberg, H. Krum, B. M. Massie, S. M. Wasserman, M.-L. Trotman, Y. Sun, et al. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia Circulation, January 29, 2008; 117(4): 526 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Okonko, A. Grzeslo, T. Witkowski, A. K.J. Mandal, R. M. Slater, M. Roughton, G. Foldes, T. Thum, J. Majda, W. Banasiak, et al. Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency: FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial J. Am. Coll. Cardiol., January 15, 2008; 51(2): 103 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lundby, J. A. L. Calbet, and P. Robach Reply from Carsten Lundby, Jose A. L. Calbet and Paul Robach J. Physiol., January 1, 2008; 586(1): 305 - 306. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Toblli, A. Lombrana, P. Duarte, and F. Di Gennaro Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1657 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Francis and A. Kanderian Anemia and Heart Failure: A New Pathway? J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1666 - 1667. [Full Text] [PDF]
|
|
|
|
|
|
D. J. van Veldhuisen, K. Dickstein, A. Cohen-Solal, D. J.A. Lok, S. M. Wasserman, N. Baker, D. Rosser, J. G.F. Cleland, and P. Ponikowski Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia Eur. Heart J., September 2, 2007; 28(18): 2208 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Murphy and K. McDonald Treatment of anaemia in chronic heart failure optimal approach still unclear Eur. Heart J., September 2, 2007; 28(18): 2185 - 2187. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Minetti, L. Agati, and W. Malorni The microenvironment can shift erythrocytes from a friendly to a harmful behavior: Pathogenetic implications for vascular diseases Cardiovasc Res, July 1, 2007; 75(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Manzone, H. Q. Dam, D. Soltis, and V. V. Sagar Blood Volume Analysis: A New Technique and New Clinical Interest Reinvigorate a Classic Study J. Nucl. Med. Technol., June 1, 2007; 35(2): 55 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C Lang and D. M Mancini Non-cardiac comorbidities in chronic heart failure Heart, June 1, 2007; 93(6): 665 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cote, M. D. Zilberberg, S. H. Mody, L. J. Dordelly, and B. Celli Haemoglobin level and its clinical impact in a cohort of patients with COPD Eur. Respir. J., May 1, 2007; 29(5): 923 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eddicks, K. Maier-Hauff, M. Schenk, A. Muller, G. Baumann, and H. Theres Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised study Heart, May 1, 2007; 93(5): 585 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Fischer, C. A. Morris, W. C. Winkelmayer, and J. Avorn Nononcologic Use of Human Recombinant Erythropoietin Therapy in Hospitalized Patients Arch Intern Med, April 23, 2007; 167(8): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Asaumi, Y. Kagaya, M. Takeda, N. Yamaguchi, H. Tada, K. Ito, J. Ohta, T. Shiroto, K. Shirato, N. Minegishi, et al. Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice Circulation, April 17, 2007; 115(15): 2022 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Shammo and F. M. Stewart Hematopoietic growth factors ASH Self-Assessment Program, January 1, 2007; 2007(1): 45 - 60. [Full Text] [PDF]
|
|
|
|
|
|
C. Lundby, J. J. Thomsen, R. Boushel, M. Koskolou, J. Warberg, J. A. L. Calbet, and P. Robach Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume J. Physiol., January 1, 2007; 578(1): 309 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lipsic, R. G. Schoemaker, P. van der Meer, A. A. Voors, D. J. van Veldhuisen, and W. H. van Gilst Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2161 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. Milani, C. J. Lavie, M. R. Mehra, and H. O. Ventura Understanding the Basics of Cardiopulmonary Exercise Testing Mayo Clin. Proc., December 1, 2006; 81(12): 1603 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Valeur, O. W. Nielsen, J. J.V. McMurray, C. Torp-Pedersen, L. Kober, and TRACE Study Group Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction Eur J Heart Fail, October 1, 2006; 8(6): 577 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Bolger, F. R. Bartlett, H. S. Penston, J. O'Leary, N. Pollock, R. Kaprielian, and C. M. Chapman Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1225 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Feng Beyond erythropoiesis: The anti-inflammatory effects of erythropoietin Cardiovasc Res, September 1, 2006; 71(4): 615 - 617. [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, G. Takemura, H. Okada, S. Miyata, R. Maruyama, L. Li, M. Higuchi, S. Minatoguchi, T. Fujiwara, and H. Fujiwara Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure Cardiovasc Res, September 1, 2006; 71(4): 684 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation, June 13, 2006; 113(23): 2713 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Komajda, S. D. Anker, A. Charlesworth, D. Okonko, M. Metra, A. Di Lenarda, W. Remme, C. Moullet, K. Swedberg, J. G.F. Cleland, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET Eur. Heart J., June 2, 2006; 27(12): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-D. Tang and S. D. Katz Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options Circulation, May 23, 2006; 113(20): 2454 - 2461. [Full Text] [PDF]
|
|
|
|
|
|
E. O'Meara, T. Clayton, M. B. McEntegart, J. J.V. McMurray, C. C. Lang, S. D. Roger, J. B. Young, S. D. Solomon, C. B. Granger, J. Ostergren, et al. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program Circulation, February 21, 2006; 113(7): 986 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Similowski, A. Agusti, W. MacNee, and B. Schonhofer The potential impact of anaemia of chronic disease in COPD Eur. Respir. J., February 1, 2006; 27(2): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Felker, W. G. Stough, L. K. Shaw, and C. M. O'Connor Anaemia and coronary artery disease severity in patients with heart failure Eur J Heart Fail, January 1, 2006; 8(1): 54 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Opasich, M. Cazzola, L. Scelsi, S. De Feo, E. Bosimini, R. Lagioia, O. Febo, R. Ferrari, A. Fucili, R. Moratti, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure Eur. Heart J., November 1, 2005; 26(21): 2232 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. George, E. Goldstein, A. Abashidze, D. Wexler, S. Hamed, H. Shmilovich, V. Deutsch, H. Miller, G. Keren, and A. Roth Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner Cardiovasc Res, November 1, 2005; 68(2): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kosiborod, J. P. Curtis, Y. Wang, G. L. Smith, F. A. Masoudi, J. M. Foody, E. P. Havranek, and H. M. Krumholz Anemia and Outcomes in Patients With Heart Failure: A Study From the National Heart Care Project Arch Intern Med, October 24, 2005; 165(19): 2237 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Clark and J. G.F. Cleland Anemia and Chronic Heart Failure: Are We Asking the Right Questions? Circulation, September 20, 2005; 112(12): 1681 - 1683. [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand, M. A. Kuskowski, T. S. Rector, V. G. Florea, R. D. Glazer, A. Hester, Y. T. Chiang, N. Aknay, A. P. Maggioni, C. Opasich, et al. Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT Circulation, August 23, 2005; 112(8): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, A. L. Clark, P. Velavan, and L. Ingle Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA Eur J Heart Fail, August 1, 2005; 7(5): 937 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. van der Meer, E. Lipsic, R. H. Henning, K. Boddeus, J. van der Velden, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, and R. G. Schoemaker Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction J. Am. Coll. Cardiol., July 5, 2005; 46(1): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38. [Full Text] [PDF]
|
|
|
|
|
|
J. George, S. Patal, D. Wexler, A. Abashidze, H. Shmilovich, T. Barak, D. Sheps, and G. Keren Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure: Comparison With Neurohormonal and Inflammatory Markers Arch Intern Med, June 13, 2005; 165(11): 1304 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Namiuchi, Y. Kagaya, J. Ohta, N. Shiba, M. Sugi, M. Oikawa, H. Kunii, H. Yamao, N. Komatsu, M. Yui, et al. High Serum Erythropoietin Level Is Associated With Smaller Infarct Size in Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1406 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O. Cheng Is There an Optimal Hematocrit Value for Cardiac Patients? J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1549 - 1549. [Full Text]
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G.F. Cleland Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review Eur. Heart J., April 2, 2005; 26(8): 778 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ishani, E. Weinhandl, Z. Zhao, D. T. Gilbertson, A. J. Collins, S. Yusuf, and C. A. Herzog Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction J. Am. Coll. Cardiol., February 1, 2005; 45(3): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Maiese, F. Li, and Z. Z. Chong New Avenues of Exploration for Erythropoietin JAMA, January 5, 2005; 293(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray and M. A. Pfeffer The year in heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Caiola and J. W. Cheng Use of Erythropoietin in Heart Failure Management Ann. Pharmacother., December 1, 2004; 38(12): 2145 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.M. Felker, K. F. Adams Jr, W. A. Gattis, and C. M. O'Connor Anemia as a risk factor and therapeutic target in heart failure J. Am. Coll. Cardiol., September 1, 2004; 44(5): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Milani, C. J. Lavie, and M. R. Mehra Cardiopulmonary Exercise Testing: How Do We Differentiate the Cause of Dyspnea? Circulation, July 27, 2004; 110(4): e27 - e31. [Full Text] [PDF]
|
|
|
|
|
|
I. Anand, J. J.V. McMurray, J. Whitmore, M. Warren, A. Pham, M. A. McCamish, and P. B.J. Burton Anemia and Its Relationship to Clinical Outcome in Heart Failure Circulation, July 13, 2004; 110(2): 149 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. van der Meer, A. A. Voors, E. Lipsic, T. D. J. Smilde, W. H. van Gilst, and D. J. van Veldhuisen Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure J. Am. Coll. Cardiol., July 7, 2004; 44(1): 63 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sharma, D. P Francis, B. Pitt, P. A Poole-Wilson, A. J.S Coats, and S. D Anker Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial Eur. Heart J., June 2, 2004; 25(12): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Z. Pantilat and A. E. Steimle Palliative Care for Patients With Heart Failure JAMA, May 26, 2004; 291(20): 2476 - 2482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. van der Meer, A. A. Voors, E. Lipsic, W. H. van Gilst, and D. J. van Veldhuisen Erythropoietin in cardiovascular diseases Eur. Heart J., February 2, 2004; 25(4): 285 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Roger, L. P. McMahon, A. Clarkson, A. Disney, D. Harris, C. Hawley, H. Healy, P. Kerr, K. Lynn, A. Parnham, et al. Effects of Early and Late Intervention with Epoetin {alpha} on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial J. Am. Soc. Nephrol., January 1, 2004; 15(1): 148 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Eltzschig, R. Ehlers, S. K. Shernan, W. Rodriguez, S. M. Silver, D. Schoevaerdts, C. Swine, D. Vanpee, M. Jessup, and S. Brozena Heart Failure N. Engl. J. Med., September 4, 2003; 349(10): 1002 - 1004. [Full Text] [PDF]
|
|
|
|
|
|
K. J Smith, A. J Bleyer, W. C Little, and D. C Sane The cardiovascular effects of erythropoietin Cardiovasc Res, September 1, 2003; 59(3): 538 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Schroecksnadel, B. Wirleitner, D. Fuchs, W. Steinborn, P. Ponikowski, S. Anker, P. van der Meer, W. H. van Gilst, D. J. van Veldhuisen, J. Ezekowitz, et al. Anemia and Congestive Heart Failure * Response Circulation, August 12, 2003; 108 (6): e41 - e42. [Full Text] [PDF]
|
|